Abstract
Aims To explore i) associations between vaping and self-reported diagnosed/suspected Covid-19; ii) changes in vaping since Covid-19 and factors associated with these changes; iii) whether Covid-19 motivated current or recent ex-vapers to quit.
Methods Cross-sectional online survey of 2791 UK adults recruited 30/04/2020–14/06/2020. Participants self-reported data on sociodemographic characteristics, diagnosed/suspected Covid-19, vaping status, changes in vaping and motivation to quit vaping since Covid-19.
Results There were no differences in diagnosed/suspected Covid-19 between never, current and ex-vapers. Bayes factors indicated there was sufficient evidence to rule out small negative (protective) associations between vaping status and diagnosed/suspected Covid-19. Among current vapers (n=397), 9.7% (95% CI 6.8-12.6%) reported vaping less than usual since Covid-19, 42.0% (37.2-46.9%) reported vaping more, and 48.3% (43.4-53.2%) reported no change. In adjusted analyses, vaping less was associated with being female (aOR=3.40, 95% CI 1.73-6.71), not living with children (aOR=4.93, 1.15-21.08) and concurrent smoking (aOR=8.77, 3.04-25.64), while vaping more was associated with being younger (aOR=5.26, 1.37-20.0), living alone (aOR=2.08, 1.14-3.85), and diagnosed/suspected Covid-19 (aOR=4.72, 2.60-8.62). Of current vapers, 32.2% (95% CI 27.5-36.8%) were motivated to quit vaping since Covid-19, partly motivated by Covid-19, and 17.4%, (9.7-26.3%) of recent ex-vapers quit vaping due to Covid-19.
Conclusions Among UK adults, self-reported diagnosed/suspected Covid-19 was not associated with vaping status. Half of current vapers changed their vaping consumption since Covid-19, with the majority reporting an increase, and a minority was motivated to quit due to Covid-19.
Registration The analysis plan was pre-registered, and it is available at https://osf.io/6j8z3/
Highlights
No difference found in diagnosed/suspected Covid-19 between never, current and ex-vapers
Half of current vapers changed their vaping consumption since Covid-19
Motivation to quit vaping was partly related to Covid-19
Competing Interest Statement
JB has received unrestricted research funding from Pfizer, who manufacture smoking cessation medications. LS has received honoraria for talks, an unrestricted research grant and travel expenses to attend meetings and workshops from Pfizer and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. All authors declare no financial links with tobacco companies or e-cigarette manufacturers or their representatives.
Funding Statement
DK, AH, OP and SJ receive salary support from Cancer Research UK (C1417/A22962). Funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been approved by UCL Research Ethics Committee at the UCL Division of Psychology and Language Sciences (PaLS) (CEHP/2020/579) as part of the larger programme: The optimisation and implementation of interventions to change behaviours related to health and the environment. All participants provided fully informed consent. The study is GDPR compliant.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon request
